According to FutureWise analysis the market for Fluorescent in Situ Hybridization (FISH) Probe in 2023 is US$ 0.89 billion, and is expected to reach US$ 1.63 billion by 2031 at a CAGR of 7.82%.
Fluorescence in situ hybridization (FISH) is a technique for recognising macromolecules that is considered a novel development in the field of cytology. It was created as a physical mapping tool to delineate genes inside chromosomes. FISH's precision and versatility have since been exploited in biological and medical studies. This aesthetically appealing technique offers a resolution that falls in between DNA analysis and chromosomal studies. A hybridising DNA probe, which can be tagged directly or indirectly, is used in FISH. Direct labelling involves the use of fluorescent nucleotides, whereas indirect labelling involves the use of reporter molecules that are then identified by fluorescent antibodies or other affinity molecules. FISH is used to detect genetic abnormalities such as different types of gene fusions, an aberrant number of chromosomes in a cell, or the loss of a chromosomal region or an entire chromosome. It's also used in a variety of scientific projects, including as gene mapping and the discovery of new oncogenes. The increasing prevalence and rising cases of cancer and genetic disorders are expected to boost the global fluorescent in situ hybridization probes market. FISH takes less time than the traditional method of cytogenetic metaphase karyotype analysis because the former requires no culture and includes processing with either fresh water or paraffin-embedded interphase nuclei. Specific cytogenetic anomalies, as well as a copy of aberration numbers, can be enumerated and sketched using this technique. Prader-Willi syndrome, Angelman syndrome, 22q13 deletion syndrome, chronic myelogenous leukaemia, acute lymphoblastic leukaemia, Cri-du-chat syndrome, Velocardiofacial syndrome, and Down syndrome are all disorders that can be detected with FISH. FISH on sperm cells is recommended for men who have an aberrant somatic or meiotic karyotype, as well as those who have oligozoospermia, because about half of oligozoospermia men have sperm chromosome abnormalities. Individuals with oligozoospermia can be identified by looking at their chromosomes 21, X, and Y. As a result, FISH is becoming an increasingly important method for detecting and monitoring specific therapies for gene anomalies, such as the discovery of the BCR/ALB1 translocation in chronic myeloid leukaemia.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Fluorescent in Situ Hybridization (FISH) Probe Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Fluorescent in Situ Hybridization (FISH) Probe Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.